AP&T: I、III和IV型胶原蛋白相关的血清学标志物与狭窄性和穿透性克罗恩病疾病进展有关

2022-08-12 xuyihan MedSci原创

克罗恩病是一种慢性的肠道炎症,可以从口腔、肛门、全消化道发生,往往最为常见的好发部位是在回盲部以及小肠,它的主要临床表现是腹痛、腹块、瘘管形成、肠梗阻。

克罗恩病 (CD) 是一种主要影响胃肠道 (GI) 的慢性炎症性肠病,主要发病机制可能与遗传易感个体的肠道微生物组有关。长期疾病活动可能会使患者的疾病发展为狭窄(即肠狭窄)和穿透性(即肠瘘、脓肿或穿孔)疾病表型,肠粘膜下层富含细胞外基质(ECM)蛋白,包括胶原蛋白,它们对于维持肠组织的上皮完整性和结构以及拉伸强度非常重要。ECM可分为两层,基底膜(BM)和间质基质(IM)。BM中最丰富的胶原蛋白是IV型胶原蛋白,而I型和III型胶原蛋白是IM中最丰富的胶原蛋白,它们与肠上皮细胞直接相关。纤维化被认为是这些疾病并发症的主要病理生理机制,这是由于过度的ECM沉积(主要是胶原蛋白)以及慢性炎症和伤口愈合受损导致的异常重塑的结果。本项研究旨在评估循环胶原蛋白形成和降解片段是否可以作为CD患者蒙特利尔疾病行为亚类的鉴别生物标志物。

研究人员收集了101名CD患者的血清样本,其中III/IV 型胶原蛋白形成(PRO-C3、PRO-C4)和基质金属蛋白酶(MMP)或颗粒酶-B(GrzB)介导的 I、III、IV 和 VI 型胶原蛋白降解产物分别为C1M、C3M、C4M,C4G、C6Ma3。101名CD患者中蒙特利尔分型分别为B1:n = 37;B2:n = 27;B3:n = 37),同时本项研究还纳入了96名对照健康人群。所有患者均随访直至最后一次门诊就诊,以监测狭窄/穿透性疾病的进展和复发以及手术干预的发生。

 

 

研究结果显示C1M、C3M 和 C4M在狭窄性疾病患者(蒙特利尔B2)中显着降低,并可以很好地将非狭窄、非穿透性 (B1) 或穿透性 (B3) 疾病患者区分开来(p< 0.001)。 同样,IV型胶原形成/降解 (PRO-C4/C4M) 比率表现出很高的辨别能力(B1/B2:AUC = 0.90;B1/B3:AUC = 0.87,p < 0.001)。同时研究人员还发现较高的C1M和C4G基线水平与穿透性疾病进展的风险增加相关(C4G:风险比 [HR] 1.71 [1.05–2.81],p< 0.05)。

本项研究证实I、III 和 IV 型胶原蛋白的降解产物增加以及IV型胶原蛋白的过度形成与狭窄的CD密切相关。I型和IV型胶原蛋白片段显示出穿透性疾病进展风险的预测潜力。这些生物标志物可能成为检测和预测狭窄和穿透性 CD 的宝贵工具。

原始出处:

Arno R. Bourgonje. et al. Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease. Alimentary Pharmacology & Therapeutics.2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1907791, encodeId=52d5190e79172, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Mar 23 23:57:21 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916562, encodeId=a57019165626a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 12 17:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841927, encodeId=6dea184192ed1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 05 23:57:21 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468999, encodeId=be8d1468999dd, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485734, encodeId=0dd71485e3452, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1907791, encodeId=52d5190e79172, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Mar 23 23:57:21 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916562, encodeId=a57019165626a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 12 17:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841927, encodeId=6dea184192ed1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 05 23:57:21 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468999, encodeId=be8d1468999dd, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485734, encodeId=0dd71485e3452, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=)]
    2022-08-12 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=1907791, encodeId=52d5190e79172, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Mar 23 23:57:21 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916562, encodeId=a57019165626a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 12 17:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841927, encodeId=6dea184192ed1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 05 23:57:21 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468999, encodeId=be8d1468999dd, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485734, encodeId=0dd71485e3452, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1907791, encodeId=52d5190e79172, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Mar 23 23:57:21 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916562, encodeId=a57019165626a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 12 17:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841927, encodeId=6dea184192ed1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 05 23:57:21 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468999, encodeId=be8d1468999dd, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485734, encodeId=0dd71485e3452, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1907791, encodeId=52d5190e79172, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Mar 23 23:57:21 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916562, encodeId=a57019165626a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 12 17:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841927, encodeId=6dea184192ed1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 05 23:57:21 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468999, encodeId=be8d1468999dd, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485734, encodeId=0dd71485e3452, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Fri Aug 12 12:57:21 CST 2022, time=2022-08-12, status=1, ipAttribution=)]

相关资讯

AP&T: 克罗恩病患者术前口服肠内营养可以优化术后结局

克罗恩病是一种原因不明的肠道炎症性疾病,在胃肠道的任何部位均可发生,但多发于末端回肠和右半结肠。本病和慢性非特异性溃疡性结肠炎两者统称为炎症性肠病(IBD)。

Clin Trans Gastroenterology:预防性抗结核治疗与接受抗TNF治疗的克罗恩病患者疾病进展加速有关

克罗恩病(crohn disease,CD),又称局限性回肠炎、局限性肠炎、节段性肠炎和肉芽肿性肠炎、也译为克隆氏病,是一种原因不明的肠道炎症性疾病。

IBD: 克罗恩病患者术后早期生物治疗与较低的内镜复发率和长期结果改善相关

克罗恩病是一种原因不明的肠道炎症性疾病,在胃肠道的任何部位均可发生,但多发于末端回肠和右半结肠。本病和慢性非特异性溃疡性结肠炎两者统称为炎症性肠病(IBD)。

JCC: 回结肠切除术后腹腔感染会增加术后克罗恩病复发的风险

腹腔感染是指一系列腹腔感染性疾病,主要包括腹腔单个脏器的感染(如急性胆囊炎、急性阑尾炎等)、腹膜炎以及腹腔脓肿,也可根据其感染涉及范围和严重程度分为单纯性腹腔感染和复杂性腹腔感染。

AJG:不同生物制剂对克罗恩病患者回肠和结肠内镜愈合的疗效比较

各类具有医研价值的碳基生物为原料,利用传统技术或现代生物技术制造,作用于人体各类生理症状的预防(保健)、治疗和诊断的各种形态制剂,统称生物制剂。